Evaluation of FOXP1 gene expression in pediatric B-cell precursor acute lymphoblastic leukemia patients at remission induction therapy

Authors

  • Alieh Fazeli Diagnostic Laboratory Sciences and Technology Research Center, School of Paramedical Sciences, Shiraz University of Medical Sciences, Shiraz, Iran
  • Gholamhossein Tamaddon Diagnostic Laboratory Sciences and Technology Research Center, School of Paramedical Sciences, Shiraz University of Medical Sciences, Shiraz, Iran
  • Mehran Bahraini Department of Hematology, Faculty of allied medicine, Iran University of Medical Sciences, Tehran, Iran
Abstract:

Background: Transcription factors (TFs) play a key role in the development, therapy, and relapse of B-cell malignancies, such as B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Given the essential function of Forkhead box protein P1 (FOXP1) transcription factor in the early development of B-cells, this study was designed to evaluate FOXP1 gene expression levels in pediatric BCP-ALL patients and NALM6 cell-line. Materials and Methods: This case-control study was done on the NALM6 cell-line and bone marrow specimens of 23 pediatric BCP-ALL patients (median age: 7.5 years; range: 2.0 – 15.0 years) at different clinical stages including new diagnosis, 15th day after the treatment, and relapse. Also, 10 healthy children were included as the control group. FOXP1 gene expression was analyzed by quantitative real-time polymerase chain reaction (qRT-PCR). The correlation analysis was performed between the FOXP1 gene expression and patients’ demographic and laboratory characteristics. Results: The results showed that FOXP1 gene expression was significantly downregulated in the NALM-6 cell-line (median=0.05, P<0.001) and patients at new diagnosis (median=0.06, p<0.0001), and relapse (median=0.001, p<0.0001) phases, compared to the control group (median=0.08). FOXP1 gene expression on the 15th day of the treatment was significantly higher than its level at the new diagnosis stage (p<0.001). Moreover, FOXP1 gene was significantly downregulated in the relapse phase compared to the new diagnosis. Patients whose number of bone marrow blasts on the 15th day of the treatment was below 5% had higher FOXP1 gene expression at the diagnosis phase (Spearman’s correlation, P<0.05, r=-0.485) and higher ratio of diagnosis/day 15 (p<0.001, Mann-Whitney U test). Conclusions: FOXP1 levels could be a potential biomarker of therapy response in remission induction therapy for pediatric BCP-ALL patients.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

Expression of ROR1 Gene in Patients with Acute Lymphoblastic Leukemia

Background: Acute lymphoblastic leukemia (ALL) results from genetic alterations in a single lymphoid progenitor cell. Expression of ROR1 is reported to be increased in ALL and mantle cell lymphoma. In this study the expression of ROR1 was assessed in newly diagnosed patients with ALL.  Methods: This study was carried out on 40 patients with newly diagnosed ALL and healthy individuals as contro...

full text

Expression Analysis of Foxo3a Gene in Pediatric Acute Lymphoblastic Leukemia in Southern Iranian Population

Background: Acute lymphoblastic leukemia (ALL), the most common childhood cancer with a peak incidence in children from 2-5 years old, might be associated with poor prognosis and resistance to therapy in specific cytogenetic backgrounds. FoxO3a, a member of the forkhead class &lsquo;O&rsquo; (FoxO) transcription factors, is a main downstream target of PI3K/AKT pathway which regulates different ...

full text

UBE2Q1, as Down Regulated Gene in Pediatric Acute Lymphoblastic Leukemia

Ubiquitin - proteasome system (UPS), the major protein degradation pathway in the cells, typically degrades short - lived and damaged proteins and regulates growth and stress responses. This pathway is altered in various cancers, including Acute Lymphoblastic Leukemia (ALL). ALL begins with a change in bone marrow cells and is the most common type of leukemia in children under 15 years. UBE2Q1...

full text

Pediatric B Cell Acute Lymphoblastic Leukemia presenting with Paraneoplastic Acute Disseminated Encephalomyelitis

Acute Disseminated Encephalomyelitis (ADEM) is a monophasic demyelinating disease most often triggered by infection or immunization, though associations with malignancy and stem cell transplant have been described. We described the case of a four-year-old boy with new-onset neurological symptoms associated with ADEM, acute leukemia, and equivocal evidence of Mycoplasma pneumoniae infection. He ...

full text

Study of Gene Expression Signatures for the Diagnosis of Pediatric Acute Lymphoblastic Leukemia (ALL) Through Gene Expression Array Analyses

Background: Acute lymphoblastic leukemia (ALL) as the most common malignancy in children is associated with high mortality and significant relapse. Currently, the non-invasive diagnosis of pediatric ALL is a main challenge in the early detection of patients. In the present study, a systems biology approach was used through network-based analysis to identify the key candidate genes related to AL...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 10  issue 4

pages  257- 265

publication date 2020-10

By following a journal you will be notified via email when a new issue of this journal is published.

Keywords

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023